At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Clinical Trial of Two Dose-levels of Itraconazole in Patients With Metastatic Castration-resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Itraconazole 200 mg and Itraconazole 300mg for Prostate Cancer. Completed, enrolled 46 participants across 4 sites.
Detailed Summary
This research is being done to test an investigational drug, called itraconazole, in the treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration (FDA) for the treatment of various fungal infections such as fingernail/toenail infections and other more serious fungal infections. The word "investigational" means that itraconazole is not approved for use in people with cancer. However, the FDA is allowing the use of itraconazole in this research study. Itraconazole has been shown to have activity against cancer (including prostate cancer) in the laboratory, but has not been tested against cancer in humans. The purpose of this study is to find out: * If itraconazole is safe when given at two different doses * How itraconazole affects prostate specific antigen (PSA): a blood test that measures substances released by prostate cancer * Whether itraconazole can delay further prostate cancer growth and spread * How itraconazole affects other markers of prostate cancer
Study Details
Timeline
Interventions
Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)